U.S. Brain Tumor Market Size To Reach $4.35 Billion By 2034

U.S. Brain Tumor Market Growth & Trends

The U.S. brain tumor market is anticipated to reach USD 4.35 billion by 2034, growing at a CAGR of 9.87% from 2025 to 2034, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of brain cancer and rising number of brain tumor diagnoses in the U.S. For instance, according to the National Brain Tumor Society report, an estimated one million Americans are currently living with a primary brain tumor, highlighting a substantial patient population in need of effective treatment options. Among these tumors, approximately 72% were classified as benign, while 28% were malignant in 2023, indicating a diverse range of treatment needs and approaches. Furthermore, according to the same source, non-malignant meningiomas represent the most prevalent type of primary non-malignant brain tumors, comprising approximately 39.7% of all brain tumors and 55.4% of all non-malignant tumors.

Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.

The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.

 Request a free sample copy or view report summary: U.S. Brain Tumor Market Report

U.S. Brain Tumor Market Report Highlights

• Based on tumor type, the malignant segment accounted for the largest revenue share in 2024 driven by the rising prevalence of brain cancer and increasing incidence of glioblastoma and high-grade malignant brain tumors

• Malignant brain tumors, including glioblastomas, often require aggressive treatment approaches, which typically involve a combination of surgery, chemotherapy, and radiation therapy

• Based on treatment type, the surgery segment accounted for the largest market share in 2024 due to several compelling factors. Firstly, surgical intervention remains the primary approach for managing many types of brain tumors, particularly malignant tumors such as glioblastomas. Surgical procedures, including craniotomy and tumor resection, aim to remove as much of the tumor as possible, which can relieve pressure on the brain, alleviate symptoms, and improve overall patient outcomes

U.S. Brain Tumor Market Segmentation

Grand View Research has segmented the U.S. brain tumor market on the basis of tumor type and treatment type:

U.S. Brain Tumor Type Outlook (Revenue, USD Million, 2024 - 2034), (Number of Patients Undergo Treatment Per Tumor Type)

• Malignant

  • Glioblastomas

  • Medulloblastomas

  • Astrocytomas

  • Ependymomas

  • Others

• Non-Malignant

  • Meningiomas

  • Pituitary Adenomas

  • Craniopharyngiomas

  • Hemangioblastomas

  • Others 

U.S. Brain Tumor Treatment Type (Malignant) Outlook (Revenue, USD Million, 2024 - 2034), (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)

• Surgery

  • Neurosurgical Instruments

  • Robotic Surgery Systems

  • Interventional Device-Based Procedures

  • Endoscopes

  • Intraoperative Imaging Systems

  • Others

• Radiation Therapy

  • External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices

    • Linear Accelerators (LINAC)

    • Gamma Knife Systems

    • Proton radiosurgery

  • Internal radiation/Brachytherapy Devices

• Interventional Device-Based Procedures

  • Embolization Devices

    • Liquid Embolic Agents

    • Microspheres

  • Tumor Ablation Devices

• Chemotherapy

• Targeted Therapy

• Tumor Treating Fields (TTF)

• Laser Interstitial Thermal Therapy (LITT)

• Surgically Targeted Radiation Therapy

• Catheter-Based Ultrasound Thermal Ablation

• Focused Ultrasound (FUS)

• Low-Intensity Focused Ultrasound (LIFU) 

U.S. Brain Tumor Treatment Type (Non-Malignant) Outlook (Revenue, USD Million, 2024 - 2034), (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)

• Surgery

  • Neurosurgical Instruments

    • Blade, Knife, Cutter & Scissors

    • Dissector

    • Drill & Perforator

    • Others

  • Robotic Surgery Systems

  • Endoscopes

  • Intraoperative Imaging Systems

  • Others

• Radiation Therapy

  • External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices

    • Linear Accelerators (LINAC)

    • Gamma Knife Systems

    • Proton radiosurgery

  • Internal radiation/Brachytherapy Devices

• Other Monitoring Devices 

List of key players in the U.S. Brain Tumor Market 

• GT Medical Technologies, Inc. 

• Novocure

• ZAP Surgical Systems, Inc.

• Aesculap, Inc. - a B. Braun company

• Accuray Incorporated

• Carthera

• Alpheus Medical Inc.

• Alpha Tau Medical Ltd

• Elekta

• IMRIS Inc. 

• Medtronic

• Monteris

• Openwater

• Acoustic MedSystems, Inc.

• NaviFUS Corp

• Insightec

• Varian Medical Systems, Inc. (Siemens Healthineers)

• RefleXion

• MagnetTx Oncology Solutions Ltd.

• NICO Corporation (Stryker)

• Terumo Interventional Systems

• Boston Scientific Corporation

• Koninklijke Philips N.V.

• IBA Worldwide